KR20220029719A - 에스트로겐-관련 수용체 알파 조절제 - Google Patents
에스트로겐-관련 수용체 알파 조절제 Download PDFInfo
- Publication number
- KR20220029719A KR20220029719A KR1020227003499A KR20227003499A KR20220029719A KR 20220029719 A KR20220029719 A KR 20220029719A KR 1020227003499 A KR1020227003499 A KR 1020227003499A KR 20227003499 A KR20227003499 A KR 20227003499A KR 20220029719 A KR20220029719 A KR 20220029719A
- Authority
- KR
- South Korea
- Prior art keywords
- methoxy
- phenyl
- pyrazolo
- pyridin
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19184515.5 | 2019-07-04 | ||
| EP19184515 | 2019-07-04 | ||
| PCT/EP2020/068574 WO2021001453A1 (en) | 2019-07-04 | 2020-07-01 | ESTROGEN-RELATED RECEPTOR ALPHA (ERRα) MODULATORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220029719A true KR20220029719A (ko) | 2022-03-08 |
Family
ID=67180693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227003499A Pending KR20220029719A (ko) | 2019-07-04 | 2020-07-01 | 에스트로겐-관련 수용체 알파 조절제 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12527774B2 (https=) |
| EP (1) | EP3994138B1 (https=) |
| JP (1) | JP7606479B2 (https=) |
| KR (1) | KR20220029719A (https=) |
| CN (1) | CN114341135B (https=) |
| AR (1) | AR119348A1 (https=) |
| AU (1) | AU2020298779A1 (https=) |
| BR (1) | BR112021026687A2 (https=) |
| CO (1) | CO2021017619A2 (https=) |
| ES (1) | ES3032908T3 (https=) |
| IL (1) | IL289510B2 (https=) |
| MA (1) | MA56444A (https=) |
| MX (1) | MX2022000165A (https=) |
| PH (1) | PH12021553204A1 (https=) |
| UA (1) | UA129204C2 (https=) |
| WO (1) | WO2021001453A1 (https=) |
| ZA (1) | ZA202200591B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023011456A1 (en) * | 2021-08-03 | 2023-02-09 | Beigene, Ltd. | Pyrazolopyridinone compounds |
| EP4486741A4 (en) | 2022-03-01 | 2026-04-08 | Insilico Medicine Ip Ltd | Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA016887B1 (ru) * | 2007-03-07 | 2012-08-30 | Янссен Фармацевтика Н.В. | ЗАМЕЩЁННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α |
| NZ579372A (en) | 2007-03-07 | 2012-02-24 | Janssen Pharmaceutica Nv | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
| CN103288823B (zh) * | 2012-02-23 | 2015-02-18 | 华东理工大学 | N,n’-芳基取代脲类化合物及其用途 |
| CN104119285B (zh) | 2013-04-28 | 2016-06-29 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| KR101819639B1 (ko) * | 2016-06-27 | 2018-01-17 | 주식회사 케미메디 | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 |
-
2020
- 2020-07-01 BR BR112021026687A patent/BR112021026687A2/pt unknown
- 2020-07-01 KR KR1020227003499A patent/KR20220029719A/ko active Pending
- 2020-07-01 MX MX2022000165A patent/MX2022000165A/es unknown
- 2020-07-01 EP EP20735186.7A patent/EP3994138B1/en active Active
- 2020-07-01 US US17/624,297 patent/US12527774B2/en active Active
- 2020-07-01 ES ES20735186T patent/ES3032908T3/es active Active
- 2020-07-01 PH PH1/2021/553204A patent/PH12021553204A1/en unknown
- 2020-07-01 JP JP2021577993A patent/JP7606479B2/ja active Active
- 2020-07-01 CN CN202080062286.XA patent/CN114341135B/zh active Active
- 2020-07-01 MA MA056444A patent/MA56444A/fr unknown
- 2020-07-01 WO PCT/EP2020/068574 patent/WO2021001453A1/en not_active Ceased
- 2020-07-01 AU AU2020298779A patent/AU2020298779A1/en active Pending
- 2020-07-01 UA UAA202200271A patent/UA129204C2/uk unknown
- 2020-07-01 IL IL289510A patent/IL289510B2/en unknown
- 2020-07-03 AR ARP200101889A patent/AR119348A1/es unknown
-
2021
- 2021-12-21 CO CONC2021/0017619A patent/CO2021017619A2/es unknown
-
2022
- 2022-01-12 ZA ZA2022/00591A patent/ZA202200591B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL289510A (en) | 2022-03-01 |
| ES3032908T3 (en) | 2025-07-28 |
| MA56444A (fr) | 2022-05-11 |
| AR119348A1 (es) | 2021-12-09 |
| JP2022538363A (ja) | 2022-09-01 |
| IL289510B2 (en) | 2025-08-01 |
| PH12021553204A1 (en) | 2022-11-07 |
| JP7606479B2 (ja) | 2024-12-25 |
| US20220387401A1 (en) | 2022-12-08 |
| CN114341135B (zh) | 2025-03-18 |
| EP3994138B1 (en) | 2025-04-02 |
| US20250268872A2 (en) | 2025-08-28 |
| UA129204C2 (uk) | 2025-02-05 |
| US12527774B2 (en) | 2026-01-20 |
| CO2021017619A2 (es) | 2022-04-19 |
| IL289510B1 (en) | 2025-04-01 |
| MX2022000165A (es) | 2022-05-20 |
| ZA202200591B (en) | 2023-07-26 |
| EP3994138C0 (en) | 2025-04-02 |
| AU2020298779A1 (en) | 2022-02-17 |
| CN114341135A (zh) | 2022-04-12 |
| BR112021026687A2 (pt) | 2022-03-08 |
| CA3144891A1 (en) | 2021-01-07 |
| EP3994138A1 (en) | 2022-05-11 |
| WO2021001453A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102614872B1 (ko) | Hpk1 억제제 및 이의 사용 방법 | |
| JP7723011B2 (ja) | イミダゾール３－オキシド誘導体系ａｃｓｓ２阻害剤及びその使用方法 | |
| KR102556742B1 (ko) | 키나제 억제제로서의 헤테로아릴 화합물 | |
| JP7606479B2 (ja) | エストロゲン関連受容体アルファ（ＥＲＲα）モジュレーター | |
| CN114630827B (zh) | 雌激素相关受体α(ERRα)调节剂 | |
| CA3144891C (en) | Estrogen-related receptor alpha (err.alpha.) modulators | |
| EA046701B1 (ru) | МОДУЛЯТОРЫ ЭСТРОГЕНСВЯЗАННЫХ РЕЦЕПТОРОВ АЛЬФА (ERRα) | |
| FR2953838A1 (fr) | Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique | |
| HK40069843A (en) | Estrogen-related receptor alpha (erralpha) modulators | |
| HK40069843B (en) | Estrogen-related receptor alpha (erralpha) modulators | |
| EP4488276A1 (en) | Novel heterocyclic compound and pharmaceutical composition comprising same | |
| HK40073444A (en) | Estrogen-related receptor alpha (err-alpha) modulators | |
| HK40073444B (en) | Estrogen-related receptor alpha (err-alpha) modulators | |
| EA047211B1 (ru) | МОДУЛЯТОРЫ СВЯЗАННОГО С ЭСТРОГЕНОМ РЕЦЕПТОРА АЛЬФА (ERRα) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |